Ketamine Works Because It Unmoors You From Yourself — And Almost Nobody Is Watching How It's Sold

You’ve maybe done ketamine before it had a waiting room. Maybe it was a bump at 2 a.m. that turned the room into taffy for twenty minutes. Maybe you’ve never touched it and the only thing you associate with the letter K is a warning label. Either way, somewhere in the last five years, a version of that same molecule started showing up in strip-mall storefronts with names like serenity spas, priced at a few hundred dollars a session, marketed as a cure for the depression nothing else touched. Both things are true about the same drug, and that’s not a coincidence — it’s the whole story.

Ketamine works, when it works, partly because it knocks you loose from yourself for forty-five minutes — and the industry now selling that experience as a $3.4 billion wellness product is operating almost entirely outside the regulatory structure built for the one FDA-approved version of it that does the same thing safely. That’s the tension underneath every ketamine clinic ad you’ve scrolled past: the drug’s most feared street effect and its most promising psychiatric effect may be the same effect, at different doses, with wildly different levels of supervision attached.

What dissociation actually is, before anyone calls it a mechanism

Strip away the clinical language and dissociation is a pretty specific, describable feeling: your sense of being located somewhere — in your body, in this room, in this hour — comes loose. People describe watching themselves from a slight distance, like there’s a thin pane of glass between them and their own hands. Time stretches or skips. The boundary between “me” and “not-me” gets porous. At low-to-moderate doses, in a supervised medical setting, that’s often described as floating, spacey, dreamlike — disorienting but not frightening, and it resolves within an hour, according to clinical observation summarized by Psychiatric Times. At high recreational doses, with no supervision and no idea when it’ll end, the same loosening becomes what users call a K-hole: a near-total collapse of the ability to move, speak, or track what’s real, which is exactly why it’s dangerous alone.

Here’s the part that matters for anyone deciding whether to try this for depression: researchers increasingly think the dissociation isn’t an unfortunate side effect you tolerate to get the antidepressant benefit — it might be doing real work. A 2020 study in Nature Communications found that patients who experienced more dissociation during a ketamine infusion tended to show a stronger antidepressant response afterward, not despite the disorientation but plausibly connected to it. The theory, still being tested and not settled science, is that depression can lock the brain into a rigid, self-critical loop — the same negative narrative playing on repeat — and a sharp jolt of dissociation temporarily interrupts the brain networks that run that loop, creating an opening where new thought patterns can take hold. That’s a real, published finding and also a genuinely open question: nobody has proven dissociation is necessary for the antidepressant effect, only that the two travel together often enough to be suspicious.

So if you’re the person who’s used this recreationally and now sees an ad for at-home ketamine lozenges promising the same clarity you chased and never found in a K-hole: the researchers agree with your instinct that something real happens in that state. What separates a $600 wellness subscription from a legitimate treatment isn’t the drug — it’s the dose, the setting, and whether anyone is in the room when it happens.

Thirty years as a battlefield drug, thirty as a club drug, now a third act

Ketamine was FDA-approved in 1970 as a field anesthetic for Vietnam, prized because medics could inject it without an IV line and it left blood pressure and breathing intact even in badly wounded soldiers — troops reportedly carried doses for each other and called it the “buddy drug,” according to The Wire Science. For three decades after, it lived two parallel lives: a Schedule III workhorse in ERs and veterinary clinics, and, under the name Special K, a club drug the DEA classified as a substance with real abuse potential. Nobody was studying it for mood disorders. Then, starting in the late 1990s, small trials showed rapid antidepressant effects in patients who’d failed everything else, and a drug filed under “anesthetic” and “drug of abuse” started acting like a psychiatric medicine — a category the system never built a lane for.

That history is why 2026 feels like a reckoning instead of just a growth story. Ketamine clinics went from fewer than 100 in 2015 to more than 1,500 by 2024, a market PharmExec put at roughly $3.4 billion by 2023 — fueled by pandemic-era telemedicine waivers, investor money, and consumer marketing that rarely mentions the word “off-label.” Every one of those infusions and lozenges for depression is off-label use: the FDA has only ever approved ketamine itself as an anesthetic. The only ketamine-derived product approved specifically for psychiatric use is esketamine, sold as Spravato, cleared in 2019 — and it comes bound to a federal Risk Evaluation and Mitigation Strategy, or REMS, that requires it be administered in a certified healthcare setting with a provider watching you for at least two hours afterward, monitoring your breathing, blood pressure, and sedation, according to the Spravato REMS program. No such federal floor exists for the ketamine clinic down the street.

No such federal floor exists for the ketamine clinic down the street.

The enforcement is catching up to the growth

Picture a patient — call her the kind of patient this boom was built to reach — who found a telehealth ketamine startup after two failed antidepressants, filled out an intake form, and never had an in-person exam before her prescription shipped. That’s not a hypothetical scenario; it’s the pattern federal regulators say some clinics ran on an industrial scale. In 2024, prosecutors in St. Louis charged Dr. Asim Ali and Dr. Mohd Malik with conspiracy to unlawfully distribute controlled substances and healthcare fraud, alleging the clinic administered ketamine under one physician’s DEA registration while that physician wasn’t even present, then billed Medicare for evaluation services patients say never happened, per PharmExec. A year earlier, the DEA suspended a prominent South Carolina telemedicine prescriber’s controlled-substance registration entirely for large-scale prescribing without adequate exams or prescription-monitoring checks.

That enforcement is arriving right as the legal scaffolding underneath it wobbles. The telemedicine waiver that let prescribers skip an in-person exam before prescribing Schedule II–V drugs has been extended four times since the pandemic and now runs through December 31, 2026, per the DEA and Federal Register — after which prescribers may again need to see patients in person absent permanent rules nobody has finalized. States aren’t waiting. Texas Medical Board rules proposed in the January 2026 Texas Register would require that “the delegating physician must be immediately available onsite for in-person consultation and emergency management throughout” psychiatric ketamine treatment, effectively banning the remote-oversight model much of the industry runs on, reports HCH Lawyers. If you’re weighing whether a clinic is legitimate, that onsite-physician standard, plus the existence of ASAM and APA clinical guidance on ketamine monitoring, is the actual bar to check a provider against — not the décor.

None of this means ketamine doesn’t work, or that everyone selling it is running a scheme. It means the drug arrived at a real psychiatric use before the country built a regulatory shape for it to live in — the same gap it fell into after Vietnam, just with a waiting room instead of a medevac. If you’re the person deciding whether to walk into one of those clinics, the question worth asking isn’t whether dissociation is safe. It’s whether the people charging you for it are prepared to sit in the room with you while it happens — because that’s the difference between a treatment and a bet. For more on how substances in this class work and where they sit clinically, see our dissociatives coverage, and for the policy fight shaping what comes next, our science and medicine desk is tracking it.